Key points are not available for this paper at this time.
To assess the safety and effectiveness of urological tumor surgeries using the hinotori™ Surgical Robot System (hinotori) in a real-world clinical setting. All surgeries including robot-assisted radical prostatectomy (RARP), robot-assisted partial nephrectomy (RAPN), robot-assisted radical nephrectomy (RARN), robot-assisted nephroureterectomy (RANU), robot-assisted adrenalectomy (RAA), and robot-assisted radical cystectomy with intracorporeal urinary diversion (RARC+ICUD) for urological tumors with the hinotori and da Vinci surgical system (da Vinci) from January 2022 to September 2023 were enrolled. We evaluated the safety and effectiveness of surgeries using the hinotori compared with those using the da Vinci. Robotic surgeries using the hinotori were performed in a total of 91 cases, comprising 42 cases of RARP, 18 cases of RAPN, six cases of RARN, 10 cases of RANU, 13 cases of RAA, and two cases of RARC+ICUD; no major intraoperative complications were observed in any of the cases using the hinotori; no major postoperative complications occurred in any of the cases; no case experienced an unrecoverable equipment error during surgery. Meanwhile, robotic surgeries using the da Vinci were performed in a total of 277 cases, comprising 126 cases of RARP, 94 cases of RAPN, 12 cases of RARN, 10 cases of RANU, 20 cases of RAA, and 15 cases of RARC+ICUD; major intraoperative complications occurred in two cases; major postoperative complications occurred in seven cases; seven cases required transfusion; one case underwent conversion to open surgery; during the study period, no case experienced an unrecoverable equipment error. Surgical outcomes for cases with the hinotori were comparable to those with the da Vinci. This study demonstrated that the hinotori is a safe and feasible tool for robotic surgeries in the field of urology.
Miyamoto et al. (Thu,) studied this question.